MD Bioproducts는 생명공학 전문 회사로, 면역학 및 염증 연구를 위한 제품과 서비스를 제공합니다.

제품 설명

ArthritoMab™ Antibody Cocktail for C57BL/6, TG, 50 mg

제품 번호

CIA-MAB-2C

제품 특징

Description

ArthritoMab™ Antibody Cocktail is a reformulated cocktail of 4 monoclonal antibodies for the induction of arthritis as an alternative to the widely used collagen-induced arthritis (CIA) model. Many transgenic strains of mice are on a C57BL/6 background. However this strain is refractory to arthritis induction either by CIA or CAIA. Traditionally to overcome this in the CAIA model an increased dose of antibody cocktail is given. This reformulated cocktail of antibodies is optimized for production of arthritis in C57BL/6, inducing arthritis with lower doses of antibody. This new formulation can also be used in other strains of mouse, which traditionally require greater amounts of cocktail.

The Collagen Antibody Induced Arthritis (CAIA) model is a relevant model for studying the efferent phase of RA, where leukocytes are attracted and respond to the immune complex in the joint. It is induced using a cocktail of antibodies to anti-CII and contains pathogenic features similar to that of RA such as pannus formation, cellular infiltration, synovitis and cartilage/bone destruction.

Download the whitepaper. 

For use with Balb/c, DBA/1, R10.RIII strains, see ArthritoMab™ Antibody Cocktail for Balb/c, DBA/1, R10.RIII, 50 mg.

Benefits of the CAIA model

• Length of study: Arthritis develops in mice typically within 24-48 hr allowing the completion of a study within 2 weeks reducing the number of assessments and scoring periods.
• Reduced group size: Rate of incidence is nearly 100% depending on the strain allowing for smaller group sizes.
• Synchronization: onset of disease is synchronized between animals simplifying treatment schedules.
• Steady & Controlled disease progression: No rapid & severe disease spikes enabling evaluation of all treatment schedules
• Susceptibility: Induce arthritis in transgenic strains with as little as 2 mg of Antibody. 

Comparison

Abbreviations:

• Anti-Collagen Induced arthritis (ACIA)
• Monoclonal Antibody induced arthritis (mAb-RA)
• Collagen Antibody Induced Arthritis (CAIA)

Download the whitepaper

Data/Specifications:

Epitope Specificity

The classic CIA model is mediated by autoantibodies which bind to type II collagen and complement. In mice as well as human RA patients, the antibody response that best correlates with disease is directed against the C1, J1 and U1 epitopes. The ArthritoMab™ arthritogenic cocktail of 4 monoclonal antibodies binds to these well-defined epitopes C11b, J1, D3 and U1, which are spread over the entire CII (CB8, CB10 and CB11 fragments). This possibly encourages better immune complex formation on the cartilage surface for the initiation of arthritis and produces consistent and predictable disease in all 4 paws (with predominance for the rear). Competitor products only recognize CB11, which produces variable disease that can contribute to unpredictable involvement in the paws (sometimes more front paw involvement and other times more rear involvement).

Susceptibility

• Balb/c
• DBA/1
• B10.RIII
• C57Bl/6

Disease Progression & Positive Controls

Disease progression is steady and controlled using ArthritoMab™ antibody cocktail, enabling investigators to evaluate various regimes. Data below was generated using Vehicle, Dexamethasone and Enbrel in the Balb/c strain (induced with 2 mg ArthritoMab™ on day 0 followed by LPS boost on day 3).